BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Huntington Bancshares Inc
NASDAQ:HBAN
|
US |
|
T
|
Takachiho Koheki Co Ltd
TSE:2676
|
JP |
BiVictriX Therapeutics PLC
Non-Reccuring Items
BiVictriX Therapeutics PLC
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Non-Reccuring Items
-£17.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Non-Reccuring Items
£9.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
